MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention

NCT02066415 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 667

Last updated 2022-10-12

Study results available
· View outcomes & findings →

Summary

To evaluate the effect of erenumab compared to placebo on the change from baseline in the number of monthly migraine days in adults with chronic migraine.

Conditions

  • Treatment for Prevention of Chronic Migraine

Interventions

BIOLOGICAL

Erenumab

Administered once a month subcutaneously by authorized investigational site study staff.

DRUG

Placebo

Administered once a month subcutaneously by authorized investigational site study staff.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-05
Primary Completion
2016-02-24
Completion
2016-04-28

Countries

  • United States
  • Canada
  • Czechia
  • Denmark
  • Finland
  • Germany
  • Norway
  • Poland
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02066415 on ClinicalTrials.gov